This letter outlines the risk minimisation materials developed to explain the corneal adverse reactions that may occur with belantamab mafodotin treatment and to provide monitoring and management guidance.
For Healthcare Professionals
Certain Risk Minimisation Materials on this website are intended for use by healthcare professionals only. By proceeding you are confirming that you are a healthcare professional.
Want to avoid this message? If you are a Healthcare professional, REGISTER or LOGIN and you will not have to self-certify when you access Risk Minimisation Materials.